Commercial Insight: Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition intensifies : Market Research Report

Commercial Insight: Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition intensifies

Published by: Datamonitor

Published: Aug. 21, 2008 - 401 Pages

ABOUT DATAMONITOR HEALTHCARE: About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Strategic scoping and focus; Datamonitor insight into the cancer therapy brands market; Related reports; Upcoming reports
CHAPTER 2 MARKET DEFINITION: Definition of the cancer market; Antihormonal therapies by ATC class; L2A3 - Luteinizing hormone-releasing hormone analogs; L2B1 - Anti-estrogens; L2B2 - Anti-androgens; L2B3 - Aromatase inhibitors; Cytotoxic therapies by ATC class; L1A - Alkylating agents; L1B - Antimetabolites; L1C - Vinca alkaloids and other plant-derived products; L1D - Antineoplastic antibiotics; L1X2 - Platinum compounds; Report classification of cytotoxic therapies; Antimetabolites; Mitotic inhibitors; DNA-interactive agents; Topoisomerase poisons; Non-covalent DNA binding drugs; Covalent DNA binding drugs - alkylating agents; Targeted therapies by ATC class; L1X3 - Antineoplastic monoclonal antibodies; L1X9 - All other antineoplastics
CHAPTER 3 MARKET OVERVIEW AND FORECASTS: Seven major markets; US; Japan; 5EU; France; Germany; Italy; Spain; UK; Rest of World snapshot
CHAPTER 4 BRAND DYNAMICS: Brand analysis by indication; Solid tumors versus hematological malignancies; Current market assessment; Future market assessment; Analysis of brand by number of approved indications; Cytotoxic therapies are the leading class of brand in terms of the number of approved indications; Analysis of indication by number of cancer therapy brands in the Top 20; Breast cancer is the dominant indication in terms of the number of approved agents in the Top 20 cancer therapy brands; Brand analysis by mode of administration; Current market assessment; Future market assessment; Brand analysis by company; A total of 30 companies are involved in the marketing of the Top 20 cancer brands in the seven major markets; AstraZeneca and Roche are the leading companies in terms of the number of marketed Top 20 cancer brands; Roche is firmly established as the leading company in the oncology market; AstraZeneca's oncology portfolio is set to experience the negative impact of patent expiry on all of its key products over the next 5 years; Co-marketed cancer therapy brands had the largest market share in 2007; Brand analysis by event; Avastin will experience the greatest number of forecast events across the seven major markets; Top 20 brands versus rest of market snapshot; Seven major markets; US; Japan; 5EU
CHAPTER 5 BRAND PROFILES AND FORECASTS: Abraxane (paclitaxel, albumin-bound formulation; Abraxis/AstraZeneca/Taiho); Alimta (pemetrexed; Eli Lilly); Arimidex (anastrozole; AstraZeneca); Aromasin (exemestane; Pfizer); Avastin (bevacizumab; Genentech/Roche/Chugai); Camptosar (irinotecan; Yakult Honsha/Daiichi Seiyaku); Casodex (bicalutamide; AstraZeneca); Dacogen (decitabine; Eisai/Johnson & Johnson); Doxil (pegylated liposomal doxorubicin; Johnson & Johnson/ Schering-Plough); Ellence (epirubicin; Pfizer/Kyowa Hakko Kogyo); Eloxatin (oxaliplatin; Sanofi-Aventis); Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono); Femara (letrozole; Novartis/Chugai); Furtulon (doxifluridine; Roche/Chugai); Gemzar (gemcitabine; Eli Lilly); Gleevec (imatinib; Novartis); Herceptin (trastuzumab; Genentech/Roche/Chugai); Iressa (gefitinib; AstraZeneca); Ixempra (ixabepilone; Bristol-Myers Squibb); Brand profile; Nexavar (sorafenib; Onyx/Bayer Schering); Nolvadex (tamoxifen; AstraZeneca); Revlimid (lenalidomide; Celgene); Rituxan (rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo); Sprycel (dasatinib; Bristol-Myers Squibb); Suprefact (buserelin; Sanofi-Aventis); Sutent (sunitinib; Pfizer); Tarceva (erlotinib; OSI/Genentech/Roche/Chugai); Tasigna (nilotinib; Novartis); Taxol (paclitaxel; Bristol-Myers Squibb); Taxotere (docetaxel; Sanofi-Aventis); Temodar (temozolomide; Schering-Plough); Thalomid (thalidomide; Celgene); TS-1 (tegafur + gimeracil + oteracil; Taiho/Sanofi-Aventis); Tykerb (lapatinib; GlaxoSmithKline); UFT (tegafur + uracil; Taiho/Merck Serono); Vectibix (panitumumab; Amgen/Takeda); Velcade (bortezomib; Takeda/Johnson & Johnson); Vidaza (azacitidine; Celgene/Nippon Shinyaku); Xeloda (capecitabine; Roche/Chugai); Zoladex (goserelin; AstraZeneca)
APPENDIX A - MARKET ASSUMPTIONS: Country-specific assumptions and events; Effect of Medicare Modernization Act in the US; Biennial price cuts in Japan; Generic erosion assumptions; Data definitions, limitations and assumptions; Standard units; Japanese market data; Derivation of sales forecasts and pricing trends; Forecasts; Forecast methodology
APPENDIX B: Bibliography; Datamonitor reports; List of tables; List of figures; Abbreviations; Report methodology; About Datamonitor; About Datamonitor Healthcare; Disclaimer
List of Figures: Figure 1: Individual country sales and market share of all cancer therapy brands in the seven major markets, 2007; Figure 2: Percentage contribution of the Top 20 cancer therapy brands to the total cancer therapy brands market in the seven major markets, 2007; Figure 3: Individual country total sales and market share of their respective Top 20 cancer therapy brands in the seven major markets, 2007; Figure 4: Total seven major market sales of all cancer therapy brands by drug class, 2007; Figure 5: Sales and market share of the Top 20 cancer therapy brands in the seven major markets by drug class, 2007; Figure 6: Sales and market share of the Top 10 cancer therapy brands in the seven major markets, 2007; Figure 7: Total forecast sales of cancer therapy brands by country in the seven major markets, 2007-2017; Figure 8: Total forecast sales and market share of cancer therapy brands by country, 2017; Figure 9: Forecast percentage contribution of the Top 20 cancer therapy brands to the total cancer therapy brands market in the seven major markets, 2017; Figure 10: Individual country total forecast sales and market share of their respective Top 20 cancer therapy brands across the seven major markets, 2017; Figure 11: Total seven major market forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 12: Total seven major market forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 13: Forecast sales and market share of the Top 20 cancer therapy brands in the seven major markets by drug class, 2017; Figure 14: Forecast sales and market share of the top 10 cancer therapy brands in the seven major markets, 2017; Figure 15: Seven major market population aged 60 and over, 2000-2050; Figure 16: Forecast incidence of cancer across the seven major pharmaceutical markets, 2001-2015; Figure 17: Global therapy sales ($m), 2007-2012; Figure 18: US sales of all cancer therapy brands by drug class, 2007; Figure 19: Sales of the Top 20 cancer therapy brands in the US by drug class, 2007; Figure 20: Sales and market share of the Top 10 cancer therapy brands in the US, 2007; Figure 21: US total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 22: US total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 23: Forecast sales and market share of the Top 20 cancer therapy brands in the US by drug class, 2017; Figure 24: Forecast sales and market share of the top 10 cancer therapy brands in the US, 2017; Figure 25: Japan sales of all cancer therapy brands by drug class, 2007; Figure 26: Sales of the Top 20 cancer therapy brands in Japan by drug class, 2007; Figure 27: Sales and market share of the Top 10 cancer therapy brands in Japan, 2007; Figure 28: Japan total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 29: Japan total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 30: Forecast sales and market share of the Top 20 cancer therapy brands in Japan by drug class, 2017; Figure 31: Forecast sales and market share of the top 10 cancer therapy brands in Japan, 2017; Figure 32: 5EU sales of all cancer therapy brands by drug class, 2007; Figure 33: Sales of the Top 20 cancer therapy brands in the 5EU by drug class, 2007; Figure 34: Sales and market share of the Top 10 cancer therapy brands in the 5EU, 2007; Figure 35: 5EU total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 36: 5EU total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 37: Forecast sales and market share of the Top 20 cancer therapy brands in the 5EU by drug class, 2017; Figure 38: Forecast sales and market share of the top 10 cancer therapy brands in the 5EU, 2017; Figure 39: France sales of all cancer therapy brands by drug class, 2007; Figure 40: Sales of the Top 20 cancer therapy brands in France by drug class, 2007; Figure 41: Sales and market share of the Top 10 cancer therapy brands in France, 2007; Figure 42: France total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 43: France total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 44: Forecast sales and market share of the Top 20 cancer therapy brands in France by drug class, 2017; Figure 45: Forecast sales and market share of the top 10 cancer therapy brands in France, 2017; Figure 46: Germany sales of all cancer therapy brands by drug class, 2007; Figure 47: Sales of the Top 20 cancer therapy brands in Germany by drug class, 2007; Figure 48: Sales and market share of the Top 10 cancer therapy brands in Germany, 2007; Figure 49: Germany total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 50: Germany total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 51: Forecast sales and market share of the Top 20 cancer therapy brands in Germany by drug class, 2017; Figure 52: Forecast sales and market share of the top 10 cancer therapy brands in Germany, 2017; Figure 53: Italy sales of all cancer therapy brands by drug class, 2007; Figure 54: Sales of the Top 20 cancer therapy brands in Italy by drug class, 2007; Figure 55: Sales and market share of the Top 10 cancer therapy brands in Italy, 2007; Figure 56: Italy total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 57: Italy total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 58: Forecast sales and market share of the Top 20 cancer therapy brands in Italy by drug class, 2017; Figure 59: Forecast sales and market share of the top 10 cancer therapy brands in Italy, 2017; Figure 60: Spain sales of all cancer therapy brands by drug class, 2007; Figure 61: Sales of the Top 20 cancer therapy brands in Spain by drug class, 2007; Figure 62: Sales and market share of the Top 10 cancer therapy brands in Spain, 2007; Figure 63: Spain total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 64: Spain total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 65: Forecast sales and market share of the Top 20 cancer therapy brands in Spain by drug class, 2017; Figure 66: Forecast sales and market share of the top 10 cancer therapy brands in Spain, 2017; Figure 67: UK sales of all cancer therapy brands by drug class, 2007; Figure 68: Sales of the Top 20 cancer therapy brands in the UK by drug class, 2007; Figure 69: Sales and market share of the Top 10 cancer therapy brands in the UK, 2007; Figure 70: UK total forecast sales of all cancer therapy brands by drug class, 2007-2017; Figure 71: UK total forecast sales and market share of all cancer therapy brands by drug class, 2017; Figure 72: Forecast sales and market share of the Top 20 cancer therapy brands in the UK by drug class, 2017; Figure 73: Forecast sales and market share of the top 10 cancer therapy brands in the UK, 2017; Figure 74: US, Japan, 5EU and RoW total cancer therapy sales and market share, 2007; Figure 75: US, Japan, 5EU and RoW antihormonal cancer therapy sales and market share, 2007; Figure 76: US, Japan, 5EU and RoW cytotoxic therapy sales and market share, 2007; Figure 77: US, Japan, 5EU and RoW targeted cancer therapy sales and market share, 2007; Figure 78: Seven major market sales of all cancer therapy brands by type of indication, 2007; Figure 79: Sales of the Top 20 cancer therapy brands in the seven major markets by type of indication, 2007; Figure 80: Forecast seven major market sales of all cancer therapy brands by type of indication, 2017; Figure 81: Forecast sales of the Top 20 cancer therapy brands in the seven major markets by type of indication, 2017; Figure 82: Analysis of brands included in the Top 20 cancer therapy brands in 2007 or 2017 by number of approved oncology indications; Figure 83: Analysis of oncology indications by number of approved brands included in the Top 20 cancer therapy brands in 2007 or 2017; Figure 84: Seven major market sales of all cancer therapy brands by mode of administration, 2007; Figure 85: Sales of Top 20 cancer therapy brands in the seven major markets by mode of administration, 2007; Figure 86: Forecast seven major market sales of all cancer therapy brands by mode of administration, 2017; Figure 87: Forecast sales of the Top 20 cancer therapy brands in the seven major markets by mode of administration, 2017; Figure 88: Analysis of companies by number of cancer therapy brands included in the Top 20 in 2007 or 2017; Figure 89: Seven major market sales of all cancer therapy brands marketed by single companies versus sales of all cancer therapy brands marketed by more than one company, 2007; Figure 90: Seven major market sales of Top 20 cancer therapy brands marketed by single companies versus sales of Top 20 cancer therapy brands marketed by more than one company, 2007; Figure 91: Analysis of Top 20 cancer therapy brands by number of forecast events, 2008-2017; Figure 92: Seven major market volume and value sales by drug class for the Top 20 brands compared to the rest of the market, 2007; Figure 93: US volume and value sales by drug class for the Top 20 brands compared to the rest of the market, 2007; Figure 94: Japan volume and value sales by drug class for the Top 20 brands compared to the rest of the market, 2007; Figure 95: 5EU volume and value sales by drug class for the Top 20 brands compared to the rest of the market, 2007

Abstract

Introduction

Cancer therapy brand sales totaled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expiries due, companies will need to work hard to maximize their return throughout the lifecycle of their brands.

Scope

Current and future overview of the cancer therapy brands market in 2007 and 2017
Individual country forecasts for the Top 20 cancer therapy brands in each of the seven major markets
Segmentation and analysis of market dynamics by country sales, drug class, indication, company and impacted events
Detailed product profiles and discussion of assumptions and events used in forecast analysis

Highlights

The Top 20 cancer therapy brands in the seven major markets contributed the majority ($26.1 billion, 85%) of cancer therapy brand sales in 2007. Datamonitor forecasts the total market to grow to $62.4 billion by 2017 at a CAGR of 7%. The Top 20 brands in 2017 will still contribute a high proportion of this (80%) with sales reaching $50.2 billion.
Targeted therapies will increasingly dominate the Top 20 cancer brands leaderboard, accounting for 12 of the Top 20 brands in the seven major markets in 2017. Datamonitor forecasts Avastin to become the leading cancer therapy brand, facilitated by further indication expansion and high physician familiarity.
Genentech/Roche are the dominant force in the market with an oncology portfolio including the three leading cancer therapy brands (Rituxan, Avastin and Herceptin). The companies are set to continue this dominance, with Rituxan, Avastin and Herceptin forecast to remain the top three brands in 2017, achieving aggregate 7MM sales of over $23 billion.

Reasons to Purchase

Understand market specific drivers and predict the future potential of key cancer therapy brands
Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics
Consider, assess and react to opportunities and risks influencing the leading cancer therapy brands

Please note, this file is delivered as an Zip file.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Commercial Insight: Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition intensifies

Table of Contents

Abstract